Hinova Pharmaceuticals Inc. (SHA:688302)
China · Delayed Price · Currency is CNY 33.15
+0.75 (2.31%)
At close: Aug 4, 2026
Hinova Pharmaceuticals Revenue
Hinova Pharmaceuticals had revenue of 26.03M CNY in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to 46.50M, up 12,574.70% year-over-year. In the year 2025, Hinova Pharmaceuticals had annual revenue of 20.47M with 5,480.12% growth.
Revenue (ttm)
46.50M
Revenue Growth
+12,574.70%
P/S Ratio
70.60
Revenue / Employee
192.93K
Employees
241
Market Cap
3.28B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 20.47M | 20.10M | 5,480.12% |
| Dec 31, 2024 | 366.84K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 1.65M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Baolingbao Biology | 2.81B |
| Kexing Biopharm | 1.46B |
| Qingdao Vland Biotech INC. | 1.40B |
| Boji Medical Technology | 949.94M |
| Zhejiang Shouxiangu Pharmaceutical | 625.30M |
| Lifecome Biochemistry | 470.43M |
| Guanhao Biotech | 386.40M |
| Jiangsu Bioperfectus Technologies | 326.02M |